1-(Naphthalen-1-yl)propan-2-amine--hydrogen chloride (1/1) | 19352-02-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(Naphthalen-1-yl)propan-2-amine--hydrogen chloride (1/1)
• 英文别名: 1-naphthalen-1-ylpropan-2-amine;hydrochloride
• CAS: 19352-02-4
• 化学式: C13H16ClN
• 分子量: 221.72
• InChiKey: XSEGXLBWQMYCAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.15
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• FOCUSTED ULTRASOUND HYPERTHERMIA
  申请人：KING'S COLLEGE LONDON

  公开号：US20180178043A1

  公开（公告）日：2018-06-28

  The invention relates to a hyperthermia (focused ultrasound—FUS) method where an energy source is applied, repeatedly, to a desired part of the body to induce hyperthermia, e.g. using image guidance. Hyperthermia is applied after a drug or biopharmaceutical (API) and/or their labelled equivalents (theranostics) and/or their drug delivery systems has been administered to the live subject to cause the enhanced tissue distribution and/or controlled release of the drug, previously encapsulated in thermo-sensitive (lipid nano)particles, to a desired site of the body. Hyperthermia (Ultrasound) is then halted, and the site of interest. Hyperthermia is then applied again using image guidance to monitor drug's accumulation in the tissue. The drug and or the drug delivery system are also labelled (for imaging) to allow real time monitoring and modulation of the API in the human body which can be used to direct and guide the FUS at the site of interest.

  本发明涉及一种高温疗法（聚焦超声波-FUS）方法，在该方法中，能量源被反复应用于身体的所需部位，以诱导高温疗法，例如使用图像引导。在给活体主体注射药物或生物制品（API）和/或它们的标记等价物（治疗诊断）和/或它们的药物递送系统后，应用高温疗法，以导致药物之前包封在热敏（脂质纳米）颗粒中的增强组织分布和/或控制释放到身体的所需部位。然后停止高温疗法（超声波），并选择感兴趣的部位。然后再次使用图像引导应用高温疗法，以监测药物在组织中的积累。药物和/或药物递送系统也被标记（用于成像），以允许实时监测和调节人体中的API，可用于引导和指导在感兴趣的部位使用FUS。
• [EN] NANOPARTICLES<br/>[FR] NANOPARTICULES
  申请人：KING'S COLLEGE LONDON

  公开号：WO2016198862A1

  公开（公告）日：2016-12-15

  The invention provides a (drug-containing) lipid nanoparticle with: (i) at least one phospholipid; (ii) at least one lysolipid; and (iii) at least one phospholipid comprising a hydrophilic polymer;and (iv) at least one structural lipid of formula (I) which has the following general structure: (I) wherein R and R' are long hydrocarbyl hydrophobic chains, Y is a linker element, and PHG is a polar head group described as large according to its van der Waals radius, and which is different from the phospholipid (i). The lipid nanoparticle can release a drug (or API) from within the lipid nanoparticleas a result of focussed ultrasound (FUS) applied continuously, at least twice, to a desired part of the body to induce hyperthermia (an increase in temperature). FUS is applied after the lipid nanoparticle containing the drug has been administered to the live subject, and causes controlled release of the drug at the desired site of the body. Ultrasound is then halted, and the site of interest allowed to cool. Ultrasound is then applied again. Lipidnanoparticles can be labelled (for MRI, NIRF imaging),enablin greal time monitoring of the drug in the human body. Imaging information can be used to direct and guide the nature of the FUS applied to the site of interest.

  本发明提供了一种（含药物的）脂质纳米粒子，其包含：（i）至少一种磷脂；（ii）至少一种溶血磷脂；（iii）至少一种包含亲水性聚合物的磷脂；以及（iv）至少一种结构脂质，其具有以下一般结构式（I）：（I）其中R和R'是长的烃基疏水链，Y是连接元素，PHG是极性头基，根据其范德华半径描述为大，且不同于磷脂（i）。脂质纳米粒子可以通过聚焦超声（FUS）在体内所需部位连续施加至少两次，诱导体温升高（发热），从而释放药物（或API）从脂质纳米粒子内部释放。在给活体主体注入含药物的脂质纳米粒子后，施加FUS会导致药物在体内所需部位的受控释放。然后停止超声，让感兴趣的部位冷却。然后再次施加超声。脂质纳米粒子可以被标记（用于MRI、NIRF成像），从而实现对人体内药物的实时监测。成像信息可以用于指导和引导施加于感兴趣部位的FUS的性质。
• Excipients in drug delivery vehicles
  申请人：Chen Guohua

  公开号：US20050106214A1

  公开（公告）日：2005-05-19

  Injectable depot gel compositions and kits that provide an excipient for modulating a release rate and stabilizing beneficial agents are provided. Methods of administering and preparing such systems are also provided. The gel compositions comprise biodegradable, bioerodible polymers and water-immiscible solvents in amounts effective to plasticize the polymers and form gels with the polymers. Suitable excipients include pH modifiers, reducing agents, and antioxidants.

  提供了可注射的蓄积凝胶组合物和套件，提供了一种辅料来调节释放速率和稳定有益剂。还提供了这种系统的管理和准备方法。凝胶组合物包括可生物降解、可生物侵蚀的聚合物和水不相混溶的溶剂，其有效量能使聚合物塑化并与聚合物形成凝胶。适当的辅料包括pH调节剂、还原剂和抗氧化剂。
• Cationic cardiolipin analoges and its use thereof
  申请人：Ahmad U. Moghis

  公开号：US20050277611A1

  公开（公告）日：2005-12-15

  The invention provides cationic cardiolipin compounds, and methods for synthesizing and using them in liposomal formulation, gene transfection, etc. In particular, the invention provides liposomes comprising cationic cardiolipin analog, pharmaceutical compositions comprising cationic cardiolipin analogs, and methods of using such liposomes and compositions, in delivering active pharmaceutical agents to treat human and animal diseases and/or in diagnostic assays.

  本发明提供了阳离子心磷脂化合物以及其合成和在脂质体制剂、基因转染等方面的使用方法。特别地，本发明提供了含阳离子心磷脂类似物的脂质体、含阳离子心磷脂类似物的药物组合物以及使用这些脂质体和组合物的方法，用于传递活性药物治疗人类和动物疾病和/或诊断测定。
• Cardiolipin molecules and methods of synthesis
  申请人：Ahmad U. Moghis

  公开号：US20050266068A1

  公开（公告）日：2005-12-01

  The invention provides new synthetic routes for cardiolipin with different fatty acids and/or alkyl chains with varying chain length and also with or without unsaturation, particularly a short-chain cardiolipin. The methods comprise reacting a 1,2-O-sn-diacyl/1,2-O-sn-dialkyl glycerol or a 2-O-protected glycerol, with a phosphoramidite reagent or a phosphate triester to produce a protected cardiolipin, which is deprotected to prepare the short chain cardiolipin. The reaction schemes can be used to generate new variants of cardiolipin. The cardiolipin prepared by the present methods can be incorporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs. Such liposomes can be used to treat diseases or in diagnostic and/or analytical assays. Liposomes can also include ligands for targeting a particular cell type or specific tissue.

  本发明提供了一种合成不同脂肪酸和/或不同链长烷基的心磷脂的新合成路线，以及具有或不具有不饱和度，特别是一种短链心磷脂。该方法包括将1,2-O-sn-二酰基/1,2-O-sn-二烷基甘油或2-O-保护甘油与磷酸酰胺试剂或磷酸三酯反应以产生受保护的心磷脂，然后去保护以制备短链心磷脂。该反应方案可用于生成心磷脂的新变体。通过本方法制备的心磷脂可以被纳入到脂质体中，这些脂质体还可以包括疏水性或亲水性药物等活性剂。这样的脂质体可以用于治疗疾病或在诊断和/或分析检测中使用。脂质体还可以包括用于靶向特定细胞类型或特定组织的配体。